Discovery and exploitation of novel targets by approved drugs

Journal of Clinical Oncology

Volumn 32, Issue 8, 2014, Pages 720-721

  Dirix, Luc ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ITRACONAZOLE; PROTEIN PATCHED 1; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; VISMODEGIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CHEMOSURGERY; DRUG APPROVAL; DRUG MECHANISM; EDITORIAL; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENE PATCHED 1; HUMAN; LOCAL THERAPY; MEDULLOBLASTOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTHENED GENE; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; FEMALE; MALE; NOTE; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; ITRACONAZOLE; MALE; SKIN NEOPLASMS;

EID: 84899629643     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.7118     Document Type: Editorial

References (13)

1. Ingham PW, McMahon AP: Hedgehog signaling in animal development: Paradigms and principles. Genes Dev 15:3059-3087, 2001 (Pubitemid 33115673)
2. Rubin LL, de Sauvage FJ: Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 5:1026-1033, 2006 (Pubitemid 44835129)
3. Hahn H, Wicking C, Zaphiropoulous PG, et al: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85:841-851, 1996 (Pubitemid 26192135)
4. von Hoff DD, LoRusso PM, Rudin CM, et al: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164-1172, 2009
5. Sekulic A, Migden MR, Oro AE, et al: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:2171-2179, 2012
6. LoRusso PM, Jimeno A, Dy G, et al: Pharmacokinetic dose-scheduling study of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 17:5774-5782, 2011
7. LoRusso PM, Rudin CM, Reddy JC, et al: Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 17:2502-2511, 2011
8. Yauch RL, Dijkgraaf GJ, Alicke B, et al: Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 326:572-574, 2009
9. Dijkgraaf GJ, Alicke B, Weinmann L, et al: Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 71:435-444, 2011
10. Bossi P, Perone F, Cortellazi B, et al: Resistance to hedgehog inhibitor through Smoothened receptor mutation in basal cell carcinoma. American Association for Cancer Research/National Cancer Institute/European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, October 19-23, 2013 (abstr PR05)
11. Kim DJ, Kim J, Spaunhurst K, et al: Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 32:745-751, 2014
12. Kim J, Tang JY, Gong R, et al: Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell 17:388-399, 2010
13. Antonarakis ES, Heath EI, Smith DC, et al: Repurposing itraconazole as a treatment for advanced prostate cancer: A noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 18:163-173, 2013